1.Current status of chemotherapy for the treatment of advanced biliary tract cancer.
Takashi SASAKI ; Hiroyuki ISAYAMA ; Yousuke NAKAI ; Kazuhiko KOIKE
The Korean Journal of Internal Medicine 2013;28(5):515-524
Chemotherapy is indispensable for the treatment of advanced biliary tract cancer. Recently, reports regarding first-line chemotherapy have increased, and first-line chemotherapy treatment has become gradually more sophisticated. Gemcitabine and cisplatin combination therapy (or gemcitabine and oxaliplatin combination therapy) have become the standard of care for advanced biliary tract cancer. Oral fluoropyrimidines have also been shown to have good antitumor effects. Gemcitabine, platinum compounds, and oral fluoropyrimidines are now considered key drugs for the treatment of advanced biliary tract cancer. Several clinical trials using molecular targeted agents are also ongoing. Combination therapy using cytotoxic agents and molecular-targeted agents has been evaluated widely. However, reports regarding second-line chemotherapy remain limited, and it has not yet been clarified whether second-line chemotherapy can improve the prognosis of advanced biliary tract cancer. Thus, there is an urgent need to establish second-line standard chemotherapy treatment for advanced biliary tract cancer. Several problems exist when assessing the results of previous reports concerning advanced biliary tract cancer. In the present review, the current status of the treatment of advanced biliary tract cancer is summarized, and several associated problems are indicated. These problems should be solved to achieve more sophisticated treatment of advanced biliary tract cancer.
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
;
Biliary Tract Neoplasms/*drug therapy/mortality/pathology
;
Disease Progression
;
Disease-Free Survival
;
Humans
;
Salvage Therapy
;
Time Factors
;
Treatment Outcome
2.EC-18, a Synthetic Monoacetyldiacylglyceride, Inhibits Hematogenous Metastasis of KIGB-5 Biliary Cancer Cell in Hamster Model.
Myung Hwan KIM ; Heung Moon CHANG ; Tae Won KIM ; Sung Koo LEE ; Jung Sun PARK ; Young Hoon KIM ; Tae Yoon LEE ; Se Jin JANG ; Chul Won SUH ; Tae Suk LEE ; Sang Hee KIM ; Sung Gyu LEE
Journal of Korean Medical Science 2009;24(3):474-480
EC-18 (monoacetyldiacylglyceride) stimulates T cell production of IL-2, IL-4, IL-12, IFN-gamma, and GM-CSF in vitro. To study the effects of these cytokines stimulated by EC-18 on cancer cells, we applied hamster biliary cancer model, a difficult cancer to treat. Cancer (KIGB-5) cells were given intravenously to produce hematogenous metastatic lung lesions which were treated with EC-18 at 10, 25, and 50 mg/kg/day respectively. The fourth group was untreated control. At 4th, 8th, and 12th week the lungs were examined. EC-18 treated groups showed only a few microscopic lung lesions and no evidence of metastatic lesion with highest dose whereas widespread gross lung lesions were observed in untreated control. To investigate whether the anti-tumor effect of EC-18 is associated with suppression of tumor cell Toll-like receptor 4 (TLR-4) expression in addition to stimulation of the immune cells, KIGB-5 cells were exposed to LPS with or without EC-18. TLR-4 mRNA and protein expression, measured by reverse transcriptase PCR (RT-PCR), real-time quantitative PCR and western blot analysis, showed suppression of TLR-4 expression in KIGB-5 cells treated with EC-18 compared with control. In conclusion, EC-18 has a significant anti-tumor effect in this experimental model of biliary cancer suggesting potential for clinical application to this difficult cancer.
Animals
;
Antineoplastic Agents/*therapeutic use
;
Biliary Tract Neoplasms/*drug therapy/pathology
;
Cricetinae
;
Cytokines/metabolism
;
Female
;
Glycerides/*therapeutic use
;
Lung/pathology
;
Neoplasm Metastasis
;
T-Lymphocytes/immunology/metabolism
;
Toll-Like Receptor 4/genetics/metabolism
;
Tumor Cells, Cultured
3.EC-18, a Synthetic Monoacetyldiacylglyceride, Inhibits Hematogenous Metastasis of KIGB-5 Biliary Cancer Cell in Hamster Model.
Myung Hwan KIM ; Heung Moon CHANG ; Tae Won KIM ; Sung Koo LEE ; Jung Sun PARK ; Young Hoon KIM ; Tae Yoon LEE ; Se Jin JANG ; Chul Won SUH ; Tae Suk LEE ; Sang Hee KIM ; Sung Gyu LEE
Journal of Korean Medical Science 2009;24(3):474-480
EC-18 (monoacetyldiacylglyceride) stimulates T cell production of IL-2, IL-4, IL-12, IFN-gamma, and GM-CSF in vitro. To study the effects of these cytokines stimulated by EC-18 on cancer cells, we applied hamster biliary cancer model, a difficult cancer to treat. Cancer (KIGB-5) cells were given intravenously to produce hematogenous metastatic lung lesions which were treated with EC-18 at 10, 25, and 50 mg/kg/day respectively. The fourth group was untreated control. At 4th, 8th, and 12th week the lungs were examined. EC-18 treated groups showed only a few microscopic lung lesions and no evidence of metastatic lesion with highest dose whereas widespread gross lung lesions were observed in untreated control. To investigate whether the anti-tumor effect of EC-18 is associated with suppression of tumor cell Toll-like receptor 4 (TLR-4) expression in addition to stimulation of the immune cells, KIGB-5 cells were exposed to LPS with or without EC-18. TLR-4 mRNA and protein expression, measured by reverse transcriptase PCR (RT-PCR), real-time quantitative PCR and western blot analysis, showed suppression of TLR-4 expression in KIGB-5 cells treated with EC-18 compared with control. In conclusion, EC-18 has a significant anti-tumor effect in this experimental model of biliary cancer suggesting potential for clinical application to this difficult cancer.
Animals
;
Antineoplastic Agents/*therapeutic use
;
Biliary Tract Neoplasms/*drug therapy/pathology
;
Cricetinae
;
Cytokines/metabolism
;
Female
;
Glycerides/*therapeutic use
;
Lung/pathology
;
Neoplasm Metastasis
;
T-Lymphocytes/immunology/metabolism
;
Toll-Like Receptor 4/genetics/metabolism
;
Tumor Cells, Cultured